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http://dxObjective: The study objective was to determine whether the application of gentamicin collagen sponges re-
duces sternal wound infections in patients undergoing cardiac surgery.
Methods: A meta-analysis of randomized controlled trials was performed.
Results: Four randomized controlled trials were eligible for inclusion. By pooling data from 4 randomized con-
trolled trials (4672 per-protocol patients), gentamicin collagen sponges reduced deep sternal wound infections
(risk ratio, 0.62; 95% confidence interval, 0.39-0.97) and any sternal wound infections (risk ratio, 0.61; confi-
dence interval, 0.39-0.98). In contrast, no benefit was demonstrated regarding superficial sternal wound infec-
tions (4 randomized controlled trials [4672 patients]; risk ratio, 0.65; 95% confidence interval, 0.34-1.25) and
all-cause mortality (3 randomized controlled trials [3994 patients]; risk ratio, 0.90; 95% confidence interval,
0.57-1.42). On the basis of data from 2 randomized controlled trials (3410 patients), gentamicin collagen
sponges also seemed to reduce surgically treated sternal wound infections (risk ratio, 0.59; 95% confidence in-
terval, 0.41-0.86). The most commonly isolated pathogens were coagulase-negative Staphylococcus spp (43%)
and Staphylococcus aureus (28%).
Conclusions: Gentamicin collagen sponges seem to reduce the sternal wound infection rate in patients under-
going cardiac surgery. The statistical heterogeneity among the existing trials underlines the need for additional
large, high-quality randomized controlled trials. (J Thorac Cardiovasc Surg 2012;144:1235-40)Sternal wound infections (SWIs) after open cardiac surgery
are relatively common and potentially grave complications,
with significant associated costs.1-3 Risk factors include
diabetes, obesity, smoking, hemodynamic instability, trans-
fusions, reoperation, prolonged operative time, prolonged
ventilation, type of operation, and others.2,4-6 Although
antimicrobial prophylaxis is routinely administered, SWIs
remain a major threat, leading surgeons to seek additional
preventive measures. Gentamicin collagen sponges (GCSs)
were developed to provide high local antibiotic
concentrations in the wound, with low serum values, thus
preventing systemic adverse events (mainly nephro-
toxicity). GCSs have been widely used for the prevention
and treatment of surgical site infections since 1985;
however, no consensus regarding their use in patients
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The Journal of Thoracic and CarThe first 2 randomized controlled trials (RCTs) evaluating
the effectiveness of GCSs in patients undergoing cardiac sur-
gery were published in 2005. The study by Friberg and col-
leagues7 (2000 patients, Sweden) reported significantly
lower SWI rates in the arm receiving GCSs, whereas the
study by Eklund and colleagues8 (542 patients, Finland)
failed to do so; this was attributed to inadequate sample
size. In 2010, a multicenter RCT from 48 US centers (1502
patients) reported no difference in SWI rates between the 2
patient arms9; this finding became the subject of heated de-
bate.10-12 An additional RCT from Germany (800 patients)
recently was performed (the first one to use placebo
collagen sponges in the control arm), again claiming that
GCSs significantly reduced SWI.13 The contradictory find-
ings of the existing trials preclude safe conclusions regarding
the effectiveness of GCSs in patients undergoing cardiac sur-
gery. In this context, we sought to systematically review the
available published evidence and synthesize the relevant data
using the methodology of meta-analysis.P
MMATERIALS AND METHODS
Literature Search
A systematic search of the literature was performed on PubMed, Sco-
pus, and clinicaltrials.gov databases in September 2011. The applied search
pattern was (gentamicin OR aminoglycoside) and (carrier OR material OR
spongeOR implant or collagen) and (cardiac OR sternal). The references of
the relevant articles, including review studies, were also hand-searched in
an attempt to identify additional potentially eligible trials. No limitation on
the year of publication was set.diovascular Surgery c Volume 144, Number 5 1235
Abbreviations and Acronyms
CDC ¼ Centers for Disease Control
CI ¼ confidence interval
GCS ¼ gentamicin collagen sponge
RCT ¼ randomized controlled trial
RR ¼ risk ratio
SWI ¼ sternal wound infection
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MStudy Selection
Literature search and study selection were independently performed
by 2 investigators (M.N.M., P.K.M.). To be eligible, a study should be an
RCT, evaluate GCS use in patients undergoing cardiac surgery, and assess
the effectiveness of GCS. Both blinded and open-label trials were consid-
ered eligible. There were no language restrictions. Unpublished studies re-
ported as abstracts in conferences were searched but not included in this
review.14
Data Extraction
Data extraction was independently performed by 2 investigators
(M.N.M., P.K.M.); any disagreement was resolved by consensus in meet-
ings with all investigators. Data were extracted regarding the study design
(methodology, exclusion criteria, follow-up), patient population and char-
acteristics, preoperative and perioperative variables (antibiotic prophy-
laxis, operation performed), and reported outcomes of each trial (any
SWI, deep SWI, superficial SWI, surgically treated SWI, mortality). A
quality assessment of the reviewed trials was also performed using the
modified Jadad criteria; studies with a score of 3 or more were considered
of high quality.15
Analyzed Outcomes: Definitions
The primary outcomes for this review were deep SWI and any SWI (de-
fined as the total of deep and superficial SWI). Superficial SWI, surgically
treated SWI, and mortality comprised secondary outcomes. All analysesFIGURE 1. Flow diagram of reviewed studies. No additional articles were
1236 The Journal of Thoracic and Cardiovascular Surwere performed on the per-protocol populations (patients who met all in-
clusion and exclusion criteria, received the intervention, and had complete
follow-up data).
SWI was defined according to the Centers for Disease Control and Pre-
vention (CDC)/National Healthcare Safety Network criteria16; briefly, it re-
fers to a sternal infection occurring within 1 month and related to the
operation, which may involve only the skin and subcutaneous tissue of
the incision (superficial SWI) or extend to the fascia and muscle layers
(deep SWI). Infections involving organ space (ie, mediastinitis) were con-
sidered deep SWI.
Statistical Methods
The statistical analyses were performed with Review Manager (Rev-
Man), version 5.1 (Copenhagen: the Nordic Cochrane Centre, the Cochrane
Collaboration, 2011). Statistical heterogeneity between studies was as-
sessed by using a chi-square test and I2; a P value less than .10 for the
chi-square test or I2 greater than 50% indicated significant heterogeneity.
Publication bias was not assessed because of the small number of included
trials.17 Pooled risk ratios (RRs) and 95% confidence intervals (CIs) were
calculated for dichotomous variables (ie, SWI) using the DerSimonian-
Laird random effects model.18 Statistical significance was set at P<.05.RESULTS
The search process generated 188 studies, of which 17
were considered potentially eligible. After detailed evalua-
tion, 4 RCTs (enrolling 4844 patients undergoing cardiac
surgery) were included in the meta-analysis (Figure 1).
The methodology and patient characteristics of the re-
viewed trials are shown in Table 1.Trial Design and Quality Assessment
Two trials were single-center (in Finland and Ger-
many),8,13 1 trial was 2-center (in Sweden),7 and 1 trial
was multicenter (48 centers in the United States).9 Two
trials had a double-blind design,7,13 and 2 trials hadidentified through hand searching. RCT, Randomized controlled trial.
gery c November 2012
TABLE 1. Methodology and patient characteristics of the reviewed trials
Trial Trial quality* Trial populationy
Intervention (per-
protocol population)y Antibiotic prophylaxis
Trial exclusion
criteriaz
Within-trial differences
among compared arms
Friberg and
colleagues7
Sweden
DC DB RCT [4] 2000 patients
Elective and emergency
cardiac and ascending
aorta surgery
FU: 2 mo
23 GCS (not
premoistened)
containing 260 mg
gentamicin vs no
sponge [983 vs 987]
Oxacillin
Cloxacillin
Mouthwash (in 1 center)
No nasal antibiotics
Aminoglycosides within
2 wk
Intervention: more likely
to have received aspirin
preoperatively and to
undergo CABG
Control: more likely to
have received oral
steroids preoperatively
Eklund and
colleagues8
Finland
SC RCT [3]
Surgeon-blinded
542 patients
Elective CABG
FU: 3 mo
GCS (premoistening NR)
containing 130 mg
gentamicin vs no
sponge [269 vs 269]
Cefuroxime (85%)
Cefuroximeþ
vancomycin (15%)
Severe renal insufficiency
(uremia or need for
dialysis) or previous
kidney transplant/redo
procedure
The compared arms were
balanced.
Bennett-Guerrero
and colleagues9
USA
MC RCT [3]
Patient-blinded
1502 patients
Elective CABG and
valvuloplasty
FU: 3 mo
23 GCS (premoistened)
containing 260 mg
gentamicin vs no
sponge [727 vs 733]
Cefazolin (53%)
Cefuroxime (24%)
Vancomycin (30%)
Ciprofloxacin (2%)
Nasal mupirocin (48%)
Chlorhexidine shower
(89%)
Mouthwash (30%)
Only adult patients at high
risk for infection
(obese or diabetic)
were enrolled.
Concomitant surgery/
preoperative cardiac
mechanical assistance
device/systemic
infection/
aminoglycosides
within 2 wk/renal
insufficiency (serum
creatinine>3 mg/dL
or need for dialysis)/
major organ
transplantation,
malignancy, or
immuno-
suppression/significant
drug or alcohol abuse/
life expectancy<3 mo
The compared arms were
balanced.
Schimmer and
colleagues13
Germany
SC DB RCT [4] 800 patients
Elective and emergency
CABG and
valvuloplasty
FU: 1 mo
GCS (not premoistened)
containing 130 mg
gentamicin vs placebo
sponge [353 vs 367]
Cefuroxime Preexisting osteitis/
immunosuppression
Control: more likely to be
female, to have
LVEF<30% and
higher preoperative
serum creatinine, and
to undergo
a reoperation
DC, Dual-center; DB, double-blind; RCT, randomized controlled trial; FU, follow-up; GCS, gentamicin collagen sponge; CABG, coronary artery bypass grafting; SC, single-
center; NR, not reported; MC, multicenter LVEF, left ventricular ejection fraction. *Trial quality assessment was performed following the modified Jadad criteria for RCTs.
The score is reported in brackets.15 yTrial population refers to the number of patients enrolled in each trial. The compared per-protocol patient arms are reported in brackets
in the ‘‘Intervention’’ column. zExclusion criteria not reported in the table but pertaining to all reviewed trials comprised hypersensitivity to gentamicin, inability to communicate
or obtain informed consent, or participation in another ongoing trial and pregnancy/lactation (apart from the trial of Eklund and colleagues8).
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Ma single-blind design (1 was surgeon-blind8 and 1 was pa-
tient-blind9). Proper allocation concealment through a pla-
cebo collagen sponge was performed in only 1 trial13; all
other trials used no sponge in the control arm. All RCTs
were considered of high quality (range, 3-4, according to
the Jadad criteria). All 4 trials reported sponsoring by the
GCS manufacturers.
Two trials enrolled patients undergoing CABG or val-
vuloplasty,9,13 1 trial enrolled only patients undergoing
CABG,8 and 1 trial enrolled patients undergoing a vari-
ety of cardiac or ascending aorta operations7; 2 trials in-
cluded both elective and emergency operations,7,13The Journal of Thoracic and Carwhereas the remaining 2 excluded patients undergoing
emergency operations.8,9 The mean follow-up of the tri-
als was 2.25 months (range, 1-3 months). Two trials
used GCSs containing 130 mg of gentamicin in the in-
tervention arm,8,13 whereas the other 2 trials used 2
sponges in each patient (260 mg gentamicin).7,9 The
GCS was reported to be premoistened in normal saline
in 1 trial.9 In all trials, intravenous prophylactic antibi-
otics were administered preoperatively (<60 minutes
from surgery) and discontinued within 48 hours; diagno-
sis of SWI was established using the CDC criteria in all
trials.diovascular Surgery c Volume 144, Number 5 1237
FIGURE 2. Forest plots depicting the RRs of SWI for GCS versus control (vertical line ¼ ‘‘no difference’’ point between the 2 regimens; squares ¼ risk
ratios; diamonds¼ pooled RRs for all RCTs; horizontal lines¼ 95%CI).GCS,Gentamicin collagen sponge;M-H,Mantel-Heinzel;CI, confidence interval;
SWI, sternal wound infection; df, degrees of freedom.
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All trials reported on the deep SWI rate. By pooling data
from the 4 trials (4672 patients), GCS use seemed to signif-
icantly reduce deep SWI rate (RR, 0.62; 95%CI, 0.39-0.97;
P¼ .04) (Figure 2). The same pattern was evident when any
SWI was considered; by pooling data from the 4 trials (4672
patients), the RR was 0.61 (95% CI, 0.39-0.98; P ¼ .04)
(Figure 2).
With regard to superficial SWI rate, GCS use demon-
strated no benefit (4 trials, 4672 patients; RR, 0.65; 95%
CI, 0.34-1.25; P ¼ .20) (Figure 2). Although only 2 trials
(3410 patients) provided data on surgically treated SWI,
GCS use seemed beneficial (RR, 0.59; 95% CI, 0.41-
0.86; P ¼ .005). In regard to all-cause mortality, when
data from 3 trials (3994 patients) were pooled, no difference
was demonstrated between the 2 arms (RR, 0.90; 95% CI,
0.57-1.42; P ¼ .66).
The extracted data on the primary and secondary out-
comes of the reviewed trials are presented in Table 2. The
most commonly isolated pathogens among patients with
a SWI were gram-positive cocci; specifically, coagulase-
negative Staphylococcus spp and Staphylococcus aureus
grew in 43% (83/193) and 28% (54/193) of all positive1238 The Journal of Thoracic and Cardiovascular Surcultures, respectively. Gram-negative bacteria were respon-
sible for 23% (44/193) of positive cultures (Table 2).
DISCUSSION
The main finding of this meta-analysis, pooling data pro-
vided by 4 published RCTs with a total of 4672 per-protocol
patients, is that the incidence of deep SWI after cardiac sur-
gery among patients treated with implantable GCSs was
significantly lower compared with controls. Specifically,
the probability for deep SWI to occur in the control arm
was 1.6 times higher than the corresponding probability in
the GCS arm. It should be noted that this difference was sig-
nificant at a level of 4% using a random effects model. No
difference was noted for superficial wound infections, but
the overall wound infection rate was significantly lower in
the GCS arm. Our findings suggest that the application of
GCSs perioperatively may be beneficial in preventing post-
operative SWIs in patients undergoing cardiac surgery.
We used the random effects model in all analyses because
of the observed statistical heterogeneity. SWI rates in the
control arms of all trials were comparable (deep SWI,
2.5%-3.5%; any SWI, 5.9%-9%; superficial SWI,
3%-6.1%). At large, the observed statistical heterogeneitygery c November 2012
TABLE 2. Reported outcomes in the reviewed trials (gentamicin collagen sponge vs control, as assessed in the per-protocol population)
Trial Any SWI Deep SWI Superficial SWI
SWI treated
surgically
Mortality
(end of follow-up) Isolated pathogens (no.,%)
Friberg and colleagues7
Sweden
4.3% vs 9%
(P<.001)
2.3% vs 3.3%
(P ¼ .2)
1.9% vs 5.7%
(P<.001)
2.1% vs 3.9%
(P ¼ .02)
1.9% vs 1.8%
(P ¼ .8)
CoNS 44/102 (43%),
S aureus 28 (27%), gram-
negative 5 (5%), other (or
multimicrobial) 25 (25%)
Eklund and colleagues8
Finland
4% vs 5.9%
(P ¼ .2)
1.9%* vs 3%*
(P ¼ .4)
2.2% vs 3%
(P ¼ .6)
NR 1.1% vs 0.4%
(P ¼ .6)
CoNS 13/17 (76%), S aureus
3 (18%), E faecalis 2
(12%).
Bennett-Guerrero and
colleagues9
USA
8.4% vs 8.6%
(P ¼ .9)
1.8% vs 2.5%
(P ¼ .4)
6.6% vs 6.1%
(P ¼ .7)
3.2% vs 4.9%
(P ¼ .09)
2.6% vs 3.6%
(P ¼ .2)
CoNS 13/59 (22%), S aureus
22 (37%, including 6
MRSA isolates (10%),
E faecalis 2 (3%), gram-
negative 37 (63%), other 8
(14%)
Schimmer and colleagues13
Germany
2.5% vs 6.5%
(P ¼ .1)
0.6% vs 3.5%
(P ¼ .01)
2% vs 3%
(P ¼ .5)
NR 2.5% CoNS 13/15 (87%), S aureus
1 (7%), P acnes 2 (13%),
gram-negative 2 (13%)y
SWI, Sternal wound infection; CoNS, coagulase-negative Staphylococcus spp; NR, not reported; MRSA, methicillin-resistant Staphylococcus aureus. *Patients in whom media-
stinitis or osteitis developed were in the deep SWI group. yRefers to the patients in whom deep SWI developed.
Mavros et al Perioperative Management
P
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cial SWI in the GCS arm of the US trial (6.6%), raising an
issue of superficial SWI misdiagnosis.9 However, trial inves-
tigators reported an apparently proper infection diagnosis
protocol, using 3 blinded infectious disease specialists in
a clinical event committee and standardized criteria, includ-
ing those from the CDC16 and the ASEPSIS scoring system
(a scoring system based on need for Additional treatment,
the presence of Serious discharge, Erythema, Purulent exu-
date, and Separation of the deep tissues, the Isolation of bac-
teria, and the duration of inpatient Stay).19
Some have argued that the US trial’s negative results may
be associated with the practice of premoistening the GCS by
dipping it in normal saline before implantation11; none of the
other trials have reported such practice. However, this expla-
nation seems unlikely taking into account that the patients’
serum gentamicin levels in the US trial were similar to those
in the Swedish trial. Patients enrolled in the US trial were all
considered at risk for SWI (obese, diabetic patients), in con-
trast with the other 3 trials; this is also unlikely to have con-
tributed to the nonappearance of benefit in the GCS arm,
especially because relevant data from the Swedish trial un-
derline the benefit of GCSs in this group of patients.7
It has also been highlighted that gram-negative pathogens
were implicated in a significant proportion of SWI in the US
trial (63% vs 0%-13% in the other trials). By taking into
account that skin flora mostly consist of gram-positive
cocci, especially of the Staphylococcus spp, this may raise
concerns that patients’ SWI was not acquired periopera-
tively, but postoperatively.12 In addition, the unique
pharmacokinetic/pharmacodynamic properties of amino-
glycosides may account for a difference in the efficacy of
gentamicin against gram-positive versus gram-negativeThe Journal of Thoracic and Carpathogens20 in the setting of local administration via a colla-
gen sponge. In general, gentamicin is active against various
gram-positive and gram-negative bacteria, such as Staphy-
lococcus spp (including methicillin-resistant S aureus), Es-
cherichia coli, Klebsiella pneumoniae, Enterobacter spp,
Pseudomonas aeruginosa, and Acinetobacter spp; however,
resistant strains have developed and disseminated.20,21
A common finding among all reviewed trials was the rel-
atively high incidence of postoperative SWI (2.5%-9%).
Although numerous modalities (preoperative topical anti-
septics, eradication of S aureus carriage, intravenous pro-
phylaxis, topical application of antibiotics, and others)
have been tried, the SWI rate has not decreased signifi-
cantly.2 In regard to antibiotic prophylaxis, there are reports
underlining that surgeons’ self-reported practice does not
conform to the existing guidelines: In an international sur-
vey, 26% of cardiac surgeons did not administer the prophy-
laxis within 60 minutes of the incision, and 14% continued
the administration even after postoperative day 4.22 In addi-
tion, it has been claimed that the standard antimicrobials
usedmay need to be reconsidered in this era of advancing an-
timicrobial resistance.21,23 Furthermore, differences in the
antimicrobial formulations used (ie, generic vs original
cefuroxime) may have an impact on the development of
SWI.24 Other strategies that may aid in reducing SWI rates
include strict glucose management, nasopharyngeal decon-
taminationwithmupirocin, skin decontaminationwith chlo-
rhexidine showers, and topical application of antibiotics (ie,
bacitracin or vancomycin) postoperatively.25,26
Study Limitations
The results of this study should be considered in view of
several limitations. First, only 4 trials were identified anddiovascular Surgery c Volume 144, Number 5 1239
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in a pooled sample size of 4672 per-protocol patients, and
were of high quality. Second, there was considerable statis-
tical heterogeneity among the trials (2 reported a significant
benefit with GCS use, and 2 reported no difference) and, to
a lesser degree, clinical heterogeneity: Two trials used 1
sponge (Table 1, 130 mg gentamicin), and 2 trials used 2
sponges (260 mg gentamicin); it should be noted that only
1 study using 130 mg and 1 study using 260 mg of gentami-
cin have managed to demonstrate a significant reduction of
SWI. This is a relatively new intervention, and dosing and
application technique need to be standardized. Last, pa-
tients enrolled in each trial received different antibiotic pro-
phylaxis regimens (Table 1).
CONCLUSIONS
Despite the limitations of this meta-analysis, it provides
evidence to support the use of GCSs for the prevention of
postoperative SWIs in patients undergoing cardiac surgery.
Synthesis of the available evidence, provided by 4 pub-
lished RCTs with a total of 4672 patients who had rather
conflicting results, showed that the incidence of postopera-
tive deep SWI among patients undergoing cardiac surgery
treated with GCSs was significantly lower compared with
controls. However, additional large, high-quality RCTs
are warranted to further elucidate this field.
The authors thank Dr Schimmer for the provision of additional
data regarding the microbiological outcomes in one of the trials.13
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